Tag: Therapeutics

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced today that it has entered into an exclusive licensing and distribution agreement (the “Agreement”) for Bentrio(TM), its nasal spray for protection against airborne viruses and allergens, with Nuance Pharma Ltd. (“Nuance”) in Chinese Mainland, Hong Kong, Macau and South Korea (the “Territory”). Under the terms of the Agreement, Altamira will initially supply Bentrio(TM) to Nuance. Nuance will make an upfront payment of $1 million and pay to Altamira development and commercial milestones of up to ... Read more

Sirnaomics Ltd. (“Sirnaomics” or “Company”, together with its subsidiaries, the “Group”, stock code: 2257.HK), the RNA therapeutics biopharmaceutical company with strong presence in both China and the U.S., and the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics, is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”) today. Sirnaomics’s listing ceremony in Suzhou: Ms. Yun Monica Zhang, China Chief Operating Officer, Board Secretary and Joint Company Secretary (Left); Dr. Yang Lu, Founder, Chairman, Executive Director, President and Chief Executive Officer (Second left); Mr. ... Read more

 Parvus Therapeutics, a biopharmaceutical company developing Navacim™ platform-based disease-specific immunoregulator therapeutics to treat autoimmune diseases by activating endogenous generation of disease-specific regulatory T cells (Tregs) without impairing normal immune system function, today announced an agreement with National Resilience, Inc. (Resilience), for the tech transfer, scale-up and GMP manufacturing of PVT201, Parvus’ lead NavacimTM drug candidate being developed to treat Primary Biliary Cholangitis. “Our collaboration with Resilience, a world class partner with facilities and expertise well matched to the Navacim manufacturing process, de-risks our CMC activities and our overall IND enabling program,” stated Peter Strumph, CEO. “Recent progress by Parvus research ... Read more